Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,949 total articles
nCino, Inc. released its inaugural AI in Banking Benchmark showing that 89% of senior banking executives foresee a dual workforce of AI agents and humans within five years. While AI adoption is widespread with 84% of banks using AI enterprise-wide, only 21% currently link AI investments to revenue gains. Data governance challenges remain a barrier …
Calidi Biotherapeutics announced that Dr. Antonio F. Santidrian, CSO, will present new data at the ASGCT conference highlighting the company's proprietary RedTail virotherapy platform and lead candidate CLD-401, which targets tumors via systemic delivery and exhibits immune activating properties. The company plans to file an IND for CLD-401 by the …
AirJoule Technologies Corporation, a NASDAQ-listed company specializing in technology that extracts water from air, will release its Q1 2026 financial results on May 14, 2026, followed by a conference call to discuss the results and answer questions on May 15, 2026. The company highlights its partnerships with GE Vernova and Carrier Global Corporat…
LiqTech International announced its Q1 2026 financial results showing a slight decline in revenue to $4.1 million compared to the prior year, and a net loss widening to $2.7 million. The company highlighted growth in commercial pool and marine water treatment markets along with a positive outlook expecting 39% to 64% revenue growth for full-year 20…
Protara Therapeutics announced its first quarter 2026 financial results with $177 million in cash and investments, supporting operations into 2028. The company plans to submit a Biologics License Application for TARA-002 in lymphatic malformations in the second half of 2027 and continues to advance clinical trials in non-muscle invasive bladder can…
Moleculin Biotech announced that the MIRACLE trial evaluating Annamycin plus cytarabine in relapsed/refractory acute myeloid leukemia (AML) is on track for first interim unblinding of data by June 30, 2026. Preliminary blinded data from 45 patients show a complete remission rate (~30%) approximately double historical rates for cytarabine alone. Rec…
Swarmer, Inc, a drone autonomy software company, reported its first quarter 2026 financial results following its successful Nasdaq IPO. The company raised $17.3 million and announced key contract wins and expansion into Japan. Despite these positive developments, revenue declined significantly due to the conclusion of a major customer engagement, w…
Diginex Limited appoints Archana Kotecha, founder of The Remedy Project, as Chief Impact Officer to enhance its human rights and supply chain due diligence capabilities amid a rapidly growing $9.6 billion market. The move supports Diginex's strategy to scale sustainable regulatory compliance solutions using advanced technologies and expands its glo…
ARS Pharmaceuticals has announced the appointment of Donn Casale as its new President, effective June 1, 2026. Casale brings 25 years of biopharmaceutical commercial leadership experience, having previously scaled successful healthcare products. His role will focus on overseeing global commercial operations and driving growth, particularly advancin…
NOVAGOLD Resources Inc. released its 2025 Sustainability Report detailing its environmental, social, and governance (ESG) performance aligned with global standards such as TCFD and TNFD. The report emphasizes NOVAGOLD's responsible advancement of the Donlin Gold project, strong community engagement, and commitment to sustainable mining development …
Esperion Therapeutics announced the presentation of new analyses at the European Atherosclerosis Society Congress 2026. The data highlights the efficacy of bempedoic acid in lowering LDL cholesterol in children with heterozygous familial hypercholesterolemia as well as factors enhancing LDL-C reduction in adults. These findings support advancing be…
Orkin Canada, a wholly owned subsidiary of Rollins, Inc., alerts Canadian homeowners to increased carpenter ant activity during spring and provides tips to prevent infestations that can cause structural wood damage. The company highlights the importance of moisture control, sealing entry points, clearing wood debris, and vegetation management to mi…
Enphase Energy, Inc. has opened U.S. pre-orders for its new IQ9S-3P Commercial Microinverter, the company's most powerful microinverter yet. Utilizing advanced gallium nitride (GaN) technology, the device supports high-wattage panels up to 770 W and is designed for three-phase 480V grid configurations. The product aims to optimize energy production…
Gildan Activewear Inc. released its 22nd Sustainability Report showcasing continued achievements under its Next Generation Sustainability strategy. In 2025, the company met its sustainable cotton sourcing goals, reduced water intensity by approximately 25%, increased recycled fiber usage, and enhanced health and safety standards with ISO certificat…
Swarmer, Inc., a U.S.-based drone autonomy software company, announced a $2.86 million contract awarded by Meta Bureau LLC to outfit over 16,000 SkyKnight quadcopter UAVs with its swarming software platform. The deal includes options to upgrade licenses potentially worth an additional $10.4 million. Swarmer's battle-tested AI-based software has sup…
Dyne Therapeutics, a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, announced its management team's participation in three major 2026 investor healthcare conferences with live fireside chats and meetings. The company is advancing clinical and preclinical programs for diseases including Duchenne muscul…
Arbutus Biopharma reported robust financial results for Q1 2026 driven by a $179 million estimated license revenue from a patent litigation settlement with Moderna. The company ended the quarter with $95.2 million in cash and equivalents. Additionally, FDA granted Fast Track designation to Arbutus's hepatitis B drug candidate imdusiran, potentially…
Pyxis Oncology, a clinical-stage biotech company focusing on difficult-to-treat cancers, announced its management team's participation in three upcoming investor conferences where they will present updates. The company is advancing its lead candidate, micvotabart pelidotin (MICVO), an antibody drug conjugate targeting tumor-specific fibronectin, cu…
Dragonfly Energy Holdings Corp. has unveiled a redesigned e-commerce website for its Battle Born Batteries brand, aiming to improve customer navigation, education, and support for both retail and commercial clients. The new platform features improved accessibility, a faster interface, expanded educational resources, and better support tools for pro…
Abeona Therapeutics reported Q1 2026 financial results with increasing commercial adoption of its gene therapy ZEVASKYN, treating three patients and expanding qualified treatment centers to six. The company licensed novel engineered T-cell technology ABO-701 targeting advanced prostate cancer, aiming to file an IND in H2 2027 while deprioritizing o…
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, announced robust Q1 2026 financial results with revenue growing 35% to $15.5 million and net income more than doubling to $2.3 million year-over-year. The company shipped a record 117 Deep TMS systems in the quarter, expanded insurer coverage including for a new accelerated protoc…
Palvella Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for serious, rare skin diseases and vascular malformations, has successfully uplisted its common stock from the Nasdaq Capital Market to the Nasdaq Global Market. This uplisting reflects the company's fulfillment of higher listing standards and aims to boos…
BriaCell Therapeutics announced the inclusion of Penn Medicine’s Abramson Cancer Center as a clinical trial location for its ongoing pivotal Phase 3 study evaluating Bria-IMT, an immunotherapy regimen for advanced breast cancer. This expansion reflects increased interest from leading cancer centers and sustained enrollment momentum, with the trial …
Hengrui Pharma and Kailera Therapeutics announced they will present clinical trial data on ribupatide, a GLP-1/GIP receptor dual agonist for obesity treatment, at the American Diabetes Association 86th Scientific Sessions in June 2026. Hengrui will share Phase 2 oral ribupatide results, while Kailera presents data from its Phase 1 bridging study su…
Altimmune, Inc. disclosed its Q1 2026 financial results highlighting robust cash reserves of approximately $535 million as of April 30, 2026. The company plans to initiate the global PERFORMA Phase 3 trial for pemvidutide targeting metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, with important data readouts from …
